for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shionogi & Co Ltd

4507.T

Latest Trade

6,045.00JPY

Change

-33.00(-0.54%)

Volume

291,300

Today's Range

6,008.00

 - 

6,078.00

52 Week Range

5,503.00

 - 

7,796.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Shionogi & Co To Buy Back Up To 2.7% Worth Of Own Shares For Up To 50 Billion Yen Through Feb 28, Cancel Them On March 13

Shionogi & Co Ltd <4507.T>::TO BUY BACK UP TO 2.7% WORTH OF OWN SHARES FOR UP TO 50 BILLION YEN THROUGH FEB 28, CANCEL THEM ON MARCH 13.

GSK Long-Acting HIV Injection Meets Goal In Late Stage Study

Aug 22 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GLAXOSMITHKLINE PLC - VIIV RESULTS POSITIVE FOR EVERY 2 MONTH INJECTION.GSK- PHASE III STUDY RESULTS OF INVESTIGATIONAL, LONG-ACTING, INJECTABLE HIV-TREATMENT TWO MONTHS REGIMEN ATLAS-2M STUDY MET ITS PRIMARY ENDPOINT.GLAXOSMITHKLINE PLC - DETAILED RESULTS FROM ATLAS-2M STUDY WILL BE PRESENTED AT AN UPCOMING SCIENTIFIC MEETING.

Shionogi & Co Adjusts Conversion Value For Euro-Yen Denominated Convertible Bonds Maturing In 2019

June 18 (Reuters) - Shionogi & Co Ltd <4507.T>::DECIDED TO ADJUST CONVERSION VALUE FOR EURO-YEN DENOMINATED CONVERTIBLE BONDS MATURING IN 2019.CONVERSION VALUE AFTER ADJUSTMENT IS 4,100.3 YEN.

Shionogi & Co Ltd - Purchased All Outstanding Shares Of Pionnier Following Conclusion Of Latest Joint Study

Shionogi & Co Ltd <4507.T>::SHIONOGI & CO LTD - PURCHASED ALL OUTSTANDING SHARES OF PIONNIER FOLLOWING CONCLUSION OF LATEST JOINT STUDY.

BRIEF-Roche Says Xofluza Is Effective At Preventing Influenza

Corrects spelling of Roche drug in headline to Xofluza:PHASE III STUDY SHOWED XOFLUZA (BALOXAVIR MARBOXIL) IS EFFECTIVE AT PREVENTING INFLUENZA INFECTION.COMPARED WITH PLACEBO, XOFLUZA TREATMENT SIGNIFICANTLY REDUCED LIKELIHOOD OF PEOPLE DEVELOPING FLU AFTER EXPOSURE TO INFECTED HOUSEHOLD MEMBER.PHASE III BLOCKSTONE STUDY, CONDUCTED BY SHIONOGI, MET ITS PRIMARY ENDPOINT.

Akili and Shionogi Announce Strategic Partnership to Develop and Commercialize Digital Therapeutics

March 7 (Reuters) - Shionogi & Co Ltd <4507.T>::AKILI AND SHIONOGI ANNOUNCE STRATEGIC PARTNERSHIP TO DEVELOP AND COMMERCIALIZE DIGITAL THERAPEUTICS IN KEY ASIAN MARKETS.AKILI- CO, SHIONOGI ANNOUNCE STRATEGIC PARTNERSHIP TO DEVELOP AND COMMERCIALIZE DIGITAL THERAPEUTICS IN KEY ASIAN MARKETS.AKILI INTERACTIVE- UPFRONT AND POTENTIAL MILESTONE PAYMENTS FOR JAPAN AND TAIWAN COMMERCIALIZATION VALUED UP TO $125 MILLION.AKILI INTERACTIVE- AKILI WILL RECEIVE SUBSTANTIAL ROYALTIES ON SALES OF THE PRODUCTS IN JAPAN AND TAIWAN.

Shionogi & Co: Bought Back 7.35 Million Shares For About 50 Billion Yen Through Dec 18

Dec 21 (Reuters) - Japan's Shionogi & Co Ltd <4507.T>::BOUGHT BACK 7.35 MILLION SHARES FOR ABOUT 50 BILLION YEN THROUGH DEC 18.

Tetra Discovery Partners And Shionogi & Co., Ltd. Collaborate On Bpn14770 Development And Commercialization

Dec 18 (Reuters) - Shionogi & Co Ltd <4507.T>::TETRA DISCOVERY PARTNERS AND SHIONOGI & CO., LTD. COLLABORATE ON BPN14770 DEVELOPMENT AND COMMERCIALIZATION.SHIONOGI & CO LTD - DEAL VALUED AT POTENTIAL $160 MILLION PLUS ROYALTIES, INCLUDING $5 MILLION IN UPFRONT PAYMENTS AND $35 MILLION IN EQUITY INVESTMENT.SHIONOGI & CO LTD - SHIONOGI GAINS REGIONAL LICENSE TO ALZHEIMER'S DRUG CANDIDATE FOR JAPAN, KOREA AND TAIWAN.SHIONOGI & CO - TETRA TO ALSO BE ELIGIBLE TO GET UP TO ADDITIONAL $120 MILLION IN DEVELOPMENT, COMMERCIALIZATION MILESTONES, AS WELL AS ROYALTIES ON SALES.SHIONOGI & CO LTD - FURTHER FINANCIAL DETAILS OF AGREEMENT WERE NOT DISCLOSED..SHIONOGI & CO - IN EXCHANGE FOR GRANTING CO DEVELOPMENT RIGHTS TO BPN14770 IN JAPAN, TAIWAN, KOREA, TETRA RECEIVED $40 MILLION IN COMBINED UPFRONT FUNDING.

Shionogi & Co Bought Back Own Shares For 10.22 Billion Yen In November

Shionogi & Co Ltd <4507.T>::BOUGHT BACK OWN SHARES FOR 10.22 BILLION YEN IN NOVEMBER.

SHIONOGI increases voting power in UMN Pharma to 20.3 pct

Oct 31(Reuters) - UMN Pharma Inc <4585.T>:Says SHIONOGI & CO LTD <<<4507.T>>> increases voting power in UMN Pharma to 20.3 percent from 4.7 percent, effective Oct. 31 .

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up